Brief: SAB Biotherapeutics Reports Q1 EPS Of $0.02

SAB Biotherapeutics

12/05/2022 21:23

May 12 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * PHASE 2 DATA FOR SAB-185 EXPECTED TO BE AVAILABLE LATER
THIS
YEAR
    * SUFFICIENT CASH ANTICIPATED TO OPERATE INTO 2023
    * FULL DATA FROM PHASE 2A TRIAL THAT EVALUATED SAB-176 FOR
TREATMENT OF SEASONAL INFLUENZA EXPECTED Q3 2022
    * Q1 EARNINGS PER SHARE $0.02

Source text for Eikon:  ID:nGNX2RvdTz 
Further company coverage:  SABS.O 

 ((Reuters.Briefs@thomsonreuters.com;))